+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dual Targeted Therapy Market by Therapy Type, Indication, Line of Therapy, Route of Administration, End User, Distribution Channel, Mechanism of Action - Global Forecast to 2030- Product Image
Dual Targeted Therapy Market by Therapy Type, Indication, Line of Therapy, Route of Administration, End User, Distribution Channel, Mechanism of Action - Global Forecast to 2030- Product Image
Sale

Dual Targeted Therapy Market by Therapy Type, Indication, Line of Therapy, Route of Administration, End User, Distribution Channel, Mechanism of Action - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015556
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dual Targeted Therapy Market grew from USD 361.28 million in 2024 to USD 460.01 million in 2025. It is expected to continue growing at a CAGR of 26.59%, reaching USD 1.48 billion by 2030.

Pioneering the Era of Dual Targeted Therapeutics

The field of dual targeted therapy has evolved from a promising concept into a pivotal pillar of modern oncology research and commercialization. By simultaneously modulating two distinct molecular pathways, these therapeutics aim to overcome resistance mechanisms that frequently hamper single-agent interventions. Recent advancements in protein engineering and antibody design have accelerated the translation of bispecific constructs and combination regimens into clinical reality. Driven by a deeper understanding of tumor heterogeneity and immune evasion, dual targeting approaches are now demonstrating compelling activity across multiple cancer types.

As healthcare systems strive for treatments that deliver durable responses with manageable safety profiles, dual targeted agents are capturing attention for their potential to fill critical gaps in current therapeutic arsenals. Investments in novel formats, from bispecific antibodies to small molecule dyads, are reshaping pipeline priorities among biopharma innovators. Against this backdrop, this executive summary outlines the key shifts, tariff implications, segmentation insights, regional dynamics, leading corporate players, actionable recommendations, and methodological rigor underpinning our comprehensive analysis of the dual targeted therapy market.

Shifting Paradigms Reshape Collaborative Cancer Treatment

Over the past five years, the dual targeted therapy landscape has undergone a profound metamorphosis. Innovations in antibody engineering pushed bispecific antibody platforms from preclinical curiosities into frontline clinical trials. Simultaneously, identification of synergistic checkpoint inhibitor pairings refined immune oncology strategies, optimizing the balance between efficacy and toxicity. Kinase inhibitor combinations also gained traction by addressing compensatory signaling pathways that drive tumor survival.

This shift was further propelled by the integration of biomarker-driven patient selection, allowing clinicians to tailor combination regimens to individual tumor profiles. Advances in diagnostic assays have enabled real-time monitoring of target engagement and adaptive resistance, enhancing the precision of dual modalities. These transformative developments have not only expanded the therapeutic toolkit but also spurred collaborative frameworks between academia and industry. Strategic alliances are accelerating time-to-market and de-risking late-stage failures, marking a new era of cooperative innovation in dual targeted therapy.

Assessing the Toll of 2025 US Tariffs on Dual Therapies

The implementation of new U.S. tariffs in 2025 has introduced an unexpected variable into the economics of dual targeted therapy development and distribution. These measures, impacting the import of critical biologic components and advanced manufacturing equipment, have led to incremental cost pressures across the supply chain. Early-stage innovators face longer timelines as they navigate higher raw material expenses and restructured vendor contracts, while established players must adjust their pricing strategies to offset margin compressions without compromising patient access.

Despite these headwinds, companies are exploring localized manufacturing hubs and alternative sourcing strategies to mitigate tariff-driven cost escalations. Collaborative consortia are emerging to share production capacity and streamline regulatory approvals, reducing redundancy and achieving economies of scale. While the short-term effect has been a tightening of development budgets, the tariff-induced disruption is catalyzing greater supply chain resilience and strategic partnerships, ultimately reinforcing the sector’s capacity to deliver dual targeted therapies to patients in need.

Unveiling Market Dimensions Across Therapy Types and Settings

Analyzing the dual targeted therapy market through therapy type reveals a spectrum from bispecific antibodies to dual kinase inhibitors, each tailored to distinct molecular targets. Bispecific antibodies lead in clinical investment, leveraging IgG like constructs to engage dual antigens. Dual checkpoint inhibitors capitalize on synergistic immune modulation, while fragment based modalities offer streamlined pharmacokinetics. The segmentation by therapeutic indication underscores concentrated activity in breast cancer, colorectal cancer, and lung cancer, where unmet needs demand innovative combination regimens.

Treatment sequencing insights highlight the evolving role of dual therapies across first line, second line, and third line and beyond, with emerging data suggesting meaningful efficacy improvements as therapies move earlier in the treatment continuum. Administration routes are diversifying from intravenous bolus and infusion to patient-friendly oral capsules and tablets, as well as subcutaneous auto injectors and prefilled syringes. The end user landscape spans ambulatory care centers, home care environments, public and private hospitals, and specialty clinics, reflecting broad adoption across care settings. Distribution channels bridge hospital pharmacies with online platforms and both chain and independent retail pharmacies. Mechanism of action segmentation emphasizes EGFR, HER2, and VEGF inhibition, illustrating the molecular precision underpinning this market’s growth trajectory.

Regional Nuances Driving Global Dual Therapy Adoption

Geographical dynamics are shaping the advancement of dual targeted therapies on a global scale. In the Americas, robust R&D investment and a favorable regulatory environment have accelerated clinical trial launches and regulatory approvals, establishing the region as a bellwether for innovation. Patient advocacy and reimbursement frameworks are also evolving to support combination regimens, driving uptake in key markets.

Europe, Middle East & Africa present a heterogeneous landscape where progressive regulatory harmonization coexists with disparate healthcare infrastructures. Collaborative initiatives between public health agencies and private stakeholders are essential to overcome access barriers and optimize pricing structures. Meanwhile, Asia-Pacific is witnessing rapid expansion fueled by emerging biotech ecosystems, government incentives, and rising incidence of targeted cancer indications. Local manufacturing partnerships and technology transfers are galvanizing capacity building, ensuring broader patient reach across the region.

Leading Innovators at the Forefront of Dual Targeting

The competitive landscape of dual targeted therapy is defined by a mix of established pharmaceutical giants and agile biotech innovators. Leading biopharmaceutical corporations are investing heavily in proprietary platforms, leveraging deep pipeline integration and global commercial capabilities. Their late-stage programs benefit from extensive datasets and robust regulatory expertise, positioning them for first-mover advantage.

At the same time, nimble biotech firms are carving out niche opportunities by focusing on novel molecular formats and rare indication subsets. Their streamlined structures enable rapid iteration and early clinical validation. Strategic partnerships between large and small entities are becoming increasingly commonplace, combining resource muscle with entrepreneurial agility. These alliances are not only expediting development timelines but also fostering cross-disciplinary innovation, ensuring a dynamic and competitive market environment.

Strategic Imperatives for Accelerating Market Leadership

Industry leaders must adopt a multifaceted playbook to capitalize on the dual targeted therapy opportunity. Rigorous portfolio prioritization is essential, aligning pipeline investments with biomarkers that predict combination efficacy. Early engagement with regulatory authorities can de-risk trial designs and expedite approval pathways. Additionally, forging manufacturing alliances and exploring regional production hubs will mitigate supply chain constraints and tariff risks.

Commercial success will hinge on strategic pricing models that reflect value-based outcomes, supported by real-world evidence generation to demonstrate cost effectiveness. Cross-functional collaboration between R&D, market access, and medical affairs teams will drive cohesive launch strategies. Finally, cultivating strategic partnerships with payers, providers, and patient groups will ensure comprehensive ecosystem alignment and sustainable adoption of dual targeted therapies.

Rigorous Approach to Dual Targeted Therapy Analysis

This analysis integrates a systematic review of peer-reviewed literature, clinical trial registries, patent filings, and regulatory submissions. Primary interviews were conducted with key opinion leaders, industry executives, and clinical investigators to validate emerging trends and interpret complex datasets. Secondary research encompassed corporate reports, financial filings, and proprietary databases, ensuring a robust foundation of quantitative and qualitative insights.

Data triangulation techniques were employed to reconcile discrepancies across sources and reinforce analytical rigor. Market segmentation was defined through established frameworks and refined via expert consultations. Regional dynamics were assessed using epidemiological data and healthcare expenditure indicators. The methodology emphasizes transparency, reproducibility, and methodological integrity, providing stakeholders with confidence in the findings and recommendations presented herein.

Synthesis of Core Insights and Strategic Outlook

The convergence of molecular innovation, strategic collaboration, and adaptive regulatory landscapes positions dual targeted therapy at the forefront of oncology’s next wave. This summary has highlighted the transformative shifts reshaping development paradigms, the financial impacts of new tariff structures, the nuanced segmentation profiles driving personalized application, and the regional variations that will dictate market entry strategies. Leading organizations are leveraging diverse mechanisms of action and dual modalities to address critical unmet needs across major cancer indications.

Looking ahead, sustained success will depend on the industry’s ability to integrate real-world evidence, refine patient selection algorithms, and orchestrate seamless supply chain networks. Those who heed the actionable recommendations outlined herein will be poised to capture the full potential of dual targeted therapy, delivering enhanced clinical outcomes and unlocking new avenues for growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Bispecific Antibodies
      • IgG Like
    • Dual Checkpoint Inhibitors
    • Dual Kinase Inhibitors
    • Fragment Based
  • Indication
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
  • Line Of Therapy
    • First Line
    • Second Line
    • Third Line And Beyond
  • Route Of Administration
    • Intravenous
      • Bolus
      • Infusion
    • Oral
      • Capsule
      • Tablet
    • Subcutaneous
      • Auto Injector
      • Pre Filled Syringe
  • End User
    • Ambulatory Care Centers
    • Home Care Settings
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Channels
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Mechanism Of Action
    • Egfr Inhibition
    • Her2 Inhibition
    • Vegf Inhibition
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Eli Lilly and Company
  • AbbVie Inc.
  • Amgen Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dual Targeted Therapy Market, by Therapy Type
8.1. Introduction
8.2. Bispecific Antibodies
8.2.1. IgG Like
8.3. Dual Checkpoint Inhibitors
8.4. Dual Kinase Inhibitors
8.5. Fragment Based
9. Dual Targeted Therapy Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
10. Dual Targeted Therapy Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line and Beyond
11. Dual Targeted Therapy Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.2.1. Bolus
11.2.2. Infusion
11.3. Oral
11.3.1. Capsule
11.3.2. Tablet
11.4. Subcutaneous
11.4.1. Auto Injector
11.4.2. Pre Filled Syringe
12. Dual Targeted Therapy Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Home Care Settings
12.4. Hospitals
12.4.1. Private Hospitals
12.4.2. Public Hospitals
12.5. Specialty Clinics
13. Dual Targeted Therapy Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Channels
13.4. Retail Pharmacy
13.4.1. Chain Pharmacy
13.4.2. Independent Pharmacy
14. Dual Targeted Therapy Market, by Mechanism of Action
14.1. Introduction
14.2. Egfr Inhibition
14.3. Her2 Inhibition
14.4. Vegf Inhibition
15. Americas Dual Targeted Therapy Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Dual Targeted Therapy Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Dual Targeted Therapy Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. F. Hoffmann-La Roche Ltd
18.3.2. Novartis AG
18.3.3. Pfizer Inc.
18.3.4. AstraZeneca PLC
18.3.5. Bristol-Myers Squibb Company
18.3.6. Merck & Co., Inc.
18.3.7. Johnson & Johnson
18.3.8. Eli Lilly and Company
18.3.9. AbbVie Inc.
18.3.10. Amgen Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. DUAL TARGETED THERAPY MARKET MULTI-CURRENCY
FIGURE 2. DUAL TARGETED THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. DUAL TARGETED THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DUAL TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DUAL TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DUAL TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY IGG LIKE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DUAL CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DUAL KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY FRAGMENT BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AUTO INJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY EGFR INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY HER2 INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DUAL TARGETED THERAPY MARKET SIZE, BY VEGF INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES DUAL TARGETED THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 81. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 82. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 83. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 85. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 87. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 88. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 89. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 93. CANADA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 98. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 161. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 162. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 164. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 167. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 168. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 173. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 174. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 177. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 180. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 185. FRANCE DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 200. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 203. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 205. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 206. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 207. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 211. ITALY DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 214. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 219. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 220. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 224. SPAIN DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 265. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 268. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 270. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 271. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 290. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 291. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 292. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 293. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 294. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 296. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 297. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 298. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 300. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 302. QATAR DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 303. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 304. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 305. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 307. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 309. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 310. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 311. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 315. FINLAND DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN DUAL TARGETED THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA DUAL TARGETED THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA DUAL TARGETED THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA

Companies Mentioned

The companies profiled in this Dual Targeted Therapy market report include:
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Eli Lilly and Company
  • AbbVie Inc.
  • Amgen Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 460.01 Million
Forecasted Market Value ( USD ) by 2030 $ 1480 Million
Compound Annual Growth Rate26.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
BCMA-targeted CAR-T Cell Therapy Market by Product Type, Line Of Therapy, End User, Distribution Channel, Manufacturing Type - Global Forecast to 2030 - Product Image

BCMA-targeted CAR-T Cell Therapy Market by Product Type, Line Of Therapy, End User, Distribution Channel, Manufacturing Type - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
Bispecific Antibodies - Global Strategic Business Report - Product Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • 104 Pages
  • Global
From
Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders - Product Image

Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

  • Book
  • Global
Combination Antibody Therapy - Global Strategic Business Report - Product Image

Combination Antibody Therapy - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.